Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.73 |
| ▸ | PPARA | Q07869 | 8/20 | 0.73 |
| ▸ | PPARG | P37231 | 5/20 | 0.73 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.68 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553175 | 0.90 | PPARD (0.73) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL1554128 | 0.88 | PPARD (0.58) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6236710 | 0.87 | PPARD (0.81) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6243598 | 0.85 | PPARD (0.82) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL5266798 | 0.84 | PPARD (0.66) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6237379 | 0.84 | PPARD (1.00) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL2109131 | 0.83 | PPARD (0.67) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL27621737 | 0.83 | PPARD (0.69) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6238582 | 0.83 | FFAR1 (0.76) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6234121 | 0.82 | PPARD (1.00) | PPARDPPARAPPARGFFAR1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735303-B1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMA INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-7576109-B2 | 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576109-B2 | 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576109-B2 | 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070060626-A1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060626-A1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060626-A1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| EP-1735303-A2 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | Aventis Pharmaceuticals, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097762-A2 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060626-A1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | PPARD, PPARA, PPARG | PPARD 1/4885PPARA 2/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.